RZLT Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (31 May 2024 @ 16:00):

Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States...

Stats
Today's Volume	264 929
Average Volume	521 850
Market Cap	161.74M
EPS	$-0.340 ( 2024-05-16 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-3.54
ATR14	$0.0170 (0.42%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-29	Evans Daron	Buy	451	Common Shares
2024-05-23	Roberts Brian Kenneth	Buy	6 000	Common Shares
2024-05-23	Roberts Brian Kenneth	Buy	1 500	Common Shares
2024-05-24	Evans Daron	Buy	2 942	Common Shares
2024-05-23	Evans Daron	Buy	58	Common Shares

INSIDER POWER
100.00
Last 96 transactions
Buy: 106 691 167 \| Sell: 58 571 575

Volume Correlation

Long: 0.10 (neutral)

Short: 0.91 (very strong)

Signal:(58.561) Expect same movement, but be aware

Rezolute, Inc. Correlation

10 Most Positive Correlations
FANG	0.96
VNOM	0.955
MTEK	0.955
XBIT	0.954
SWAV	0.952
IVCB	0.944
PWP	0.943
PRIM	0.943
ENTX	0.943
APP	0.94

10 Most Negative Correlations
AKTX	-0.961
HAIN	-0.961
SIRI	-0.961
FXNC	-0.953
XPON	-0.947
ADTN	-0.946
NLSP	-0.945
SFST	-0.945
BSBK	-0.943
EMBC	-0.942

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Rezolute, Inc. Correlation - Currency/Commodity

0.16
( neutral )

-0.08
( neutral )

0.00
( neutral )

0.09
( neutral )

-0.20
( neutral )

Rezolute, Inc. Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-382 000 (0.00 %)
EPS:	$-1.010

FY	2023
Revenue:	$0
Gross Profit:	$-382 000 (0.00 %)
EPS:	$-1.010

FY	2022
Revenue:	$0
Gross Profit:	$-256 000 (0.00 %)
EPS:	$-2.13

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-2.72

Financial Reports:

No articles found.

Rezolute, Inc. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Rezolute, Inc.

Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, a selective and potent plasma kallikrein inhibitor, which is in Phase 1 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.